Regeneron plots $800M New York production push—along with 1,500 new jobs


Regeneron is investing $800M in its New York operations to keep up with the growth of its flagship eye med Eylea and fast-launching immunology drug Dupixent.


The company is planning a statewide expansion of its production facilities, including the final phase of its East Greenbush site. In all, Regeneron expects to add 1,500 workers to its workforce spread over three sites by 2024.


Read the full article at…


Comments are closed.

More in Ashton Tweed Connection
Number of female biotech CEOs remains ‘shockingly low,’ putting spotlight on BIO

Female CEOs remain exceedingly rare in the drug industry, accounting for less than 10% of biotech's top leaders. A recent...